Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297493 | 0.93 | AOC3 (0.63) | AOC3LMNAKDM4EL3MBTL1RET | |
| SCHEMBL9729386 | 0.93 | AOC3 (0.63) | AOC3LMNAKDM4EL3MBTL1RET | |
| SCHEMBL14065068 | 0.83 | AOC3 (0.70) | AOC3LMNAKDM4EL3MBTL1RET | |
| SCHEMBL11420730 | 0.81 | AOC3 (0.60) | AOC3LMNAKDM4EL3MBTL1RET | |
| SCHEMBL5417971 | 0.81 | AOC3 (0.60) | AOC3LMNAKDM4EL3MBTL1RET | |
| SCHEMBL25596758 | 0.80 | AOC3 (0.46) | AOC3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL22807616 | 0.79 | AOC3 (0.63) | AOC3LMNAKDM4EL3MBTL1RIPK1 | |
| Hydrochloric Acid SCHEMBL9737723 | 0.79 | AOC3 (0.58) | AOC3LMNAKDM4EL3MBTL1RIPK1 | |
| SCHEMBL9641990 | 0.79 | KDM4E (0.54) | AOC3LMNAKDM4EL3MBTL1RET | |
| SCHEMBL4407771 | 0.79 | AOC3 (0.53) | AOC3LMNAKDM4EL3MBTL1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHEAL W (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHEAL W (DE) | 2023-04-27 | — | — | US | disclosed |
| WO-2021195126-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHAEL W (DE) | 2021-09-30 | — | — | WO | disclosed |
| US-20200262857-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | CTSA, GAA, SLC7A5 | AOC3 2372/4885LMNA 4327/4885KDM4E 3394/4885 |
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | CTSA, ALOX15, ALOX5 | AOC3 1811/4885LMNA 4335/4885KDM4E 3648/4885 |
| US-20200262857-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | CTSA, ALOX15, ALOX5 | AOC3 1811/4885LMNA 4335/4885KDM4E 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.